About this Journal Submit a Manuscript Table of Contents
Gastroenterology Research and Practice
Volume 2013 (2013), Article ID 932478, 6 pages
http://dx.doi.org/10.1155/2013/932478
Research Article

Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan

1Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan
2Division of General Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan

Received 14 July 2013; Accepted 5 September 2013

Academic Editor: Chao-Hung Kuo

Copyright © 2013 Wei-Chen Tai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Y. Graham, G. M. Lew, P. D. Klein et al., “Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study,” Annals of Internal Medicine, vol. 116, no. 9, pp. 705–708, 1992. View at Scopus
  2. S. K. Chuah, F. W. Tsay, P. I. Hsu, and D. C. Wu, “A new look at anti-Helicobacter pylori therapy,” World Journal of Gastroenterology, vol. 17, no. 35, pp. 3971–3975, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. C. H. Kuo, P. I. Hsu, F. C. Kuo, et al., “Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial,” Journal of Antimicrobial Chemotherapy, vol. 68, pp. 222–228, 2013.
  4. P. I. Hsu, D. C. Wu, J. Y. Wu, and D. Y. Graham, “Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days?” Helicobacter, vol. 16, no. 2, pp. 146–152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Y. Graham and L. Fischbach, “Helicobacter pylori treatment in the era of increasing antibiotic resistance,” Gut, vol. 59, no. 8, pp. 1143–1153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Y. Graham, H. Lu, and Y. Yamaoka, “A report card to grade Helicobacter pylori therapy,” Helicobacter, vol. 12, no. 4, pp. 275–278, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Yamaoka, D. Y. Graham, and H. Lu, “Should triple therapy for Helicobacter pylori infection be abandoned as no longer effective?” The American Journal of Gastroenterology, vol. 4, pp. 65–67, 2008.
  8. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., “Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report,” Gut, vol. 61, no. 5, pp. 646–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. T. H. Hu, S. K. Chuah, P. I. Hsu et al., “Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori,” The American Journal of the Medical Sciences, vol. 342, no. 3, pp. 177–181, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. P. I. Hsu, D. C. Wu, J. Y. Wu, and D. Y. Graham, “Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 Days,” Helicobacter, vol. 16, no. 2, pp. 139–145, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. C. H. Kuo, H. M. Hu, F. C. Kuo et al., “Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial,” Journal of Antimicrobial Chemotherapy, vol. 63, no. 5, pp. 1017–1024, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. K. M. Fock, P. Katelaris, K. Sugano et al., “Second Asia-Pacific Conference. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection,” Journal of Gastroenterology and Hepatology, vol. 24, no. 10, pp. 1587–1600, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. P. Gisbert and F. De La Morena, “Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 1, pp. 35–44, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. H. C. Cheng, W. L. Chang, W. Y. Chen, H. B. Yang, J. J. Wu, and B. S. Sheu, “Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy,” Helicobacter, vol. 12, no. 4, pp. 359–363, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. S. K. Chuah, P. I. Hsu, K. C. Chang et al., “Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori,” Helicobacter, vol. 17, no. 3, pp. 216–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Yakoob, S. Abid, W. Jafri, Z. Abbas, M. Islam, and Z. Ahmad, “Comparison of biopsy-based methods for the detection of Helicobacter pylori infection,” British Journal of Biomedical Science, vol. 63, no. 4, pp. 159–162, 2006. View at Scopus
  17. N. J. Peng, K. H. Lai, R. S. Liu et al., “Clinical significance of oral urease in diagnosis of H. pylori infection by 13C-urea breath test,” Digestive Diseases and Sciences, vol. 46, no. 8, pp. 1772–1778, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Bilardi, P. Dulbecco, P. Zentilin et al., “A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial,” Clinical Gastroenterology and Hepatology, vol. 2, no. 11, pp. 997–1002, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. R. W. Schrauwen, M. J. Janssen, and W. A. de Boer, “Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication,” The Netherlands Journal of Medicine, vol. 67, no. 3, pp. 96–101, 2009. View at Scopus
  20. S. di Caro, F. Franceschi, A. Mariani et al., “Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication,” Digestive and Liver Disease, vol. 41, no. 7, pp. 480–485, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. J. P. Gisbert, A. Pérez-Aisa, F. Bermejo, et al., “Second-line therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: time trends in a Spanish multicenter study of 1000 patients,” Journal of Clinical Gastroenterology, vol. 47, pp. 130–135, 2013.
  22. P. I. Hsu, K. H. Lai, H. H. Tseng et al., “Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 2, pp. 195–201, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Yahav, H. Shmuely, Y. Niv, J. Bechor, and Z. Samra, “In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure,” Diagnostic Microbiology and Infectious Disease, vol. 55, no. 1, pp. 81–83, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Antos, W. Schneider-Brachert, E. Bästlein et al., “7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity,” Helicobacter, vol. 11, no. 1, pp. 39–45, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. J. P. Gisbert, ““Rescue” regimens after Helicobacter pylori treatment failure,” World Journal of Gastroenterology, vol. 14, no. 35, pp. 5385–5402, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Tanaka, E. Isogai, H. Isogai et al., “Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori,” Journal of Antimicrobial Chemotherapy, vol. 49, no. 6, pp. 1039–1040, 2002. View at Scopus
  27. M. Guslandi, “Review article: alternative antibacterial agents for Helicobacter pylori eradication,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 10, pp. 1543–1547, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Matsumoto, I. Miki, N. Aoyama et al., “Levofloxacin-versus metronidazole-based rescue therapy for H. pylori infection in Japan,” Digestive and Liver Disease, vol. 37, no. 11, pp. 821–825, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. L. G. Coelho, L. D. Moretzsohn, W. L. Vieira et al., “New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study,” Alimentary Pharmacology and Therapeutics, vol. 21, no. 6, pp. 783–787, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Marzio, D. Coraggio, S. Capodicasa, L. Grossi, and G. Cappello, “Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole,” Helicobacter, vol. 11, no. 4, pp. 237–242, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. W. M. Wong, Q. Gu, K. M. Chu et al., “Lansoprazole, levofloxacin and amoxicillin triple therapy versus quadruple therapy as second-line treatment of resistant Helicobacter pylori infection,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 3, pp. 421–427, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. J. M. Kim, J. S. Kim, N. Kim, S. G. Kim, H. C. Jung, and I. S. Song, “Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients,” International Journal of Antimicrobial Agents, vol. 28, no. 1, pp. 6–13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. W. C. Tai, T. H. Hu, C. H. Lee, H.-H. Chen, C. C. Huang, and S.-K. Chuah, “Ano-perianal tuberculosis: 15 years of clinical experiences in Southern Taiwan,” Colorectal Disease, vol. 12, no. 7, pp. e114–e120, 2010. View at Scopus
  34. J. M. Liou, C. C. Chen, M. J. Chen et al., “Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 8, pp. 1847–1852, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Miehlke, S. Krasz, W. Schneider-Brachert et al., “Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection,” Helicobacter, vol. 16, no. 6, pp. 420–426, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. K. Chuah, W. C. Tai, P. I. Hsu, et al., “The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-days levofloxacin/amoxicillin/protonpumpinhibitors—a pilot study,” Helicobacter, vol. 17, pp. 374–381, 2012.